Curi Bio

Curi Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://curibio.com

Last Round

Series B

Dec 2, 2025

Total Funding Raised

$24.4M

Momentum Score

50 /100

Company Overview

Curi Bio is a biotechnology company that provides a preclinical discovery platform combining human stem cells, systems, and data to accelerate the discovery of new medicines.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotech Equipment, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

iPSC3D engineered tissuespreclinical drug discoverycontract research organizationCROhuman-relevant modelsorgan-on-a-chip3D cell culturedrug safety testingiPSC-derived cardiomyocytesphenotypic screeningcardiac safety assessmentbioengineering platformcontractility analysispotency assaysanalytical instrumentscell line engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Curi Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Curi Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BDec 2, 2025
GrantAug 23, 2023
Series ADec 29, 2021

Key People

Founding team and executive leadership

Nicholas Geisse

Chief Executive Officer

Executive Team

Curi Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    Launched a commercially available HCM isogenic pair.

  • Mar 20, 2026

    Partnered with Battelle to commercialize NMJ assay technology.

Curi Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Curi Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Curi Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range58
Year Founded2015
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.